DPH Stock Overview Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Dechra Pharmaceuticals PLC Competitors Price History & Performance
Summary of share price highs, lows and changes for Dechra Pharmaceuticals Historical stock prices Current Share Price UK£38.66 52 Week High UK£41.46 52 Week Low UK£24.73 Beta 0.78 1 Month Change 0.68% 3 Month Change 1.84% 1 Year Change 32.40% 3 Year Change 5.57% 5 Year Change 60.15% Change since IPO 2,828.79%
Recent News & Updates Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 20
Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 18
Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million. Apr 12 Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH). Jan 17
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP) See more updates Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 20
Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 18
Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million. Apr 12 Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH). Jan 17
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP) Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024 Dec 27
Dechra Pharmaceuticals Plc Announces Directorate Change Nov 29
Dechra Pharmaceuticals Plc Announces Directorate Change Nov 28
Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023 Sep 27 Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director Jun 17 Dechra Pharmaceuticals Intends to Delist from Official List Jun 03
Consensus EPS estimates fall by 10% Mar 09
Upcoming dividend of UK£0.13 per share at 1.6% yield Mar 02
First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022) Feb 28
Investor sentiment improved over the past week Jan 13
Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company Dec 21
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index Dec 19
Now 22% undervalued after recent price drop Dec 06
Now 21% undervalued after recent price drop Nov 17
Less than half of directors are independent Nov 16
Upcoming dividend of UK£0.33 per share Oct 20 Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023
Full year 2022 earnings: EPS misses analyst expectations Sep 06
Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022 Sep 05
Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis. Aug 31 Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.
Now 21% undervalued after recent price drop Jun 16
Dechra Pharmaceuticals PLC Announces Executive Changes May 18
Less than half of directors are independent Apr 27
Non-Executive Chairman recently bought UK£99k worth of stock Apr 09
Consensus EPS estimates increase by 17% Feb 28
Upcoming dividend of UK£0.12 per share Feb 24
First half 2022 earnings: EPS misses analyst expectations Feb 22
Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022 Feb 22
Dechra Pharmaceuticals plc Announces Executive Changes Feb 17
Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc. Jan 12 Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
Non-Executive Director Denise Goode has left the company Dec 01
Upcoming dividend of UK£0.29 per share Oct 21
CFO & Executive Director exercised options and sold UK£102k worth of stock Oct 08
CEO, MD & Executive Director exercised options and sold UK£841k worth of stock Sep 24
Board Member recently sold UK£875k worth of stock Sep 15
Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020) Sep 07
Consensus EPS estimates increase to UK£0.52 Jul 15
Price target increased to UK£44.46 Jul 12
Board Member recently sold UK£963k worth of stock Apr 17
First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020) Feb 23
Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C Feb 10
New 90-day high: UK£37.44 Feb 10 Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021 Shareholder Returns DPH GB Pharmaceuticals GB Market 7D 0.2% -1.5% -1.5% 1Y 32.4% -2.8% 3.5%
See full shareholder returns
Return vs Market: DPH exceeded the UK Market which returned -6.7% over the past year.
Price Volatility Is DPH's price volatile compared to industry and market? DPH volatility DPH Average Weekly Movement 0.5% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: DPH has not had significant price volatility in the past 3 months.
Volatility Over Time: DPH's weekly volatility has decreased from 6% to 0% over the past year.
About the Company Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases.
Show more Dechra Pharmaceuticals PLC Fundamentals Summary How do Dechra Pharmaceuticals's earnings and revenue compare to its market cap? DPH fundamental statistics Market cap UK£4.40b Earnings (TTM ) -UK£27.90m Revenue (TTM ) UK£761.50m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DPH income statement (TTM ) Revenue UK£761.50m Cost of Revenue UK£331.90m Gross Profit UK£429.60m Other Expenses UK£457.50m Earnings -UK£27.90m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -0.24 Gross Margin 56.42% Net Profit Margin -3.66% Debt/Equity Ratio 64.6%
How did DPH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/01/16 08:32 End of Day Share Price 2024/01/16 00:00 Earnings 2023/06/30 Annual Earnings 2023/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Dechra Pharmaceuticals PLC is covered by 21 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Samuel England Berenberg Laurent Gelebart BNP Paribas Exane Brian White Cantor Fitzgerald Europe
Show 18 more analysts 
